Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR3 | P32745 | 18/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.45 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.45 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.45 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.45 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3807240 | 1.00 | SSTR3 (0.46) | SSTR3KCNH2CACNA1FCACNA1DCACNA1S | |
| SCHEMBL13244716 | 0.80 | SSTR3 (0.69) | SSTR3KCNH2CACNA1FCACNA1DCACNA1S | |
| SCHEMBL3020297 | 0.77 | SSTR3 (0.49) | SSTR3KCNH2CACNA1FCACNA1DCACNA1S | |
| SCHEMBL6717602 | 0.74 | SSTR3 (0.65) | SSTR3KCNH2CACNA1FCACNA1DCACNA1S | |
| SCHEMBL6717600 | 0.74 | SSTR3 (0.65) | SSTR3KCNH2CACNA1FCACNA1DCACNA1S | |
| SCHEMBL6716252 | 0.72 | SSTR3 (0.69) | SSTR3KCNH2 | |
| SCHEMBL3010196 | 0.72 | SSTR3 (0.50) | SSTR3KCNH2CACNA1FCACNA1DCACNA1S | |
| SCHEMBL3008099 | 0.72 | SSTR3 (0.45) | SSTR3KCNH2 | |
| SCHEMBL6716256 | 0.72 | SSTR3 (0.69) | SSTR3KCNH2 | |
| SCHEMBL13244752 | 0.72 | SSTR3 (0.48) | SSTR3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184758-A1 | BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2010-07-22 | — | — | US | disclosed |
| US-20100184758-A1 | BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2010-07-22 | — | — | US | disclosed |
| US-20100184758-A1 | BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2010-07-22 | — | — | US | disclosed |
| WO-2009011836-A1 | BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | MERCK & CO., INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184758-A1 | BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | GPR119, SSTR3, SSTR2 | SSTR3 2/4885KCNH2 618/4885CACNA1F 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.